Sleep Apnea
Conditions
Keywords
sleep apnea,, oxidative stress
Brief summary
Obstructive Sleep Apnea (OSA) is the most common sleep disorder affecting up to 9-24 percent of middle aged adults, and is becoming increasingly implicated in the pathogenesis of hypertension, and other cardiovascular disorders. Up to half of patients with OSA have hypertension, and their risk of developing hypertension increases with the increasing severity of Sleep Apnea. Patients with OSA and no hypertension have endothelial dysfunction, which is believed to be the precursor for most cardiovascular disorders. The upper airway collapse and obstruction that occur in OSA result in a pattern of intermittent hypoxia, that has been shown to be the cause of the hypertension, and endothelial dysfunction found in patients with OSA. Intermittent hypoxia results in oxidative stress, which in turn is linked to the pathogenesis of hypertension and endothelial dysfunction. This protocol evaluates the role of the oxidative stress in endothelial function and blood pressure in patients with OSA. This is a pilot clinical study that will compare oxidative stress parameters, and endothelial function in patients with OSA before starting treatment with continuous positive airway pressure (CPAP) and 12 weeks post being on CPAP. These patients will be compared to control patients with no history of OSA. the study does not involve assignement to different treatments. All patients will receive the indicated treatment for OSA and measurements will be collected before and 12 weeks after adequate treatment.
Detailed description
Obstructive Sleep Apnea (OSA) is increasingly recognized as a cardiovascular risk factor. OSA is a cause of hypertension and has strong association with atherosclerosis, coronary heart disease, diabetes stroke , and fatal cardiovascular events. Endothelial dysfunction is a preclinical vascular abnormality that predicts subsequent development of vascular disease . Patients with OSA demonstrate endothelial dysfunction in the absence of any manifested vascular disease . The mechanism of endothelial dysfunction in OSA is largely unknown. Endothelial dysfunction in OSA is reversible with antioxidants, suggesting a role for oxidant overproduction in the decreased NO availability in OSA. This provides parallels to other cardiovascular diseases in which oxidative stress induced endothelial dysfunction is important. Recent studies reported evidence of dysfunction or decreased expression of endothelial nitric oxide synthase (eNOS) in association with increased peroxynitrite in harvested venous endothelial cells of OSA patients. We endeavored to perform the first direct quantification of microvascular endothelial genes from OSA patients. We hypothesized that patients with OSA who are free of any cardiovascular disease will have early functional changes in the microcirculatory endothelial cells that are associated with OSA, and therefore would resolve with treatment. Given the role of oxidative stress in the vascular disease of OSA, we expected to find evidence of superoxide overproduction in the microcirculatory vessels. We expected these functional changes to be reversible with treatment of OSA. Measurement of superoxide will be done on the subcutaneous biopsy tissue using quantitative Polymerase Chain Reaction (qPCR) and immunohistochemistry techniques and image analysis software. Measurement of endothelial function will be done using Doppler ultrasound.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Completed sleep study - Older than 18
Exclusion criteria
* Hypertension * Diabetes * coronary disease * Peripheral vascular disease * High cholesterol * Smoking * Pregnancy * Use of erectile dysfunction medications or supplements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Flow Mediated Dilation | Baseline and 12 weeks | A non-invasive test using an ultrasound to measure baseline resting vessel diameter and vessel wall dilation in upper arm post application of an inflated blood pressure cuff for five minutes. The percentage change in vessel wall dilation due to stimulation from the resting vessel diameter will be calculated for each group of participants. The results will be compared relative to each group of participants. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Peroxynitrite Deposition in the Vascular Walls | baseline and 12 weeks | A forearm biopsy will be collected to isolate human microcirculatory endothelial cells. The stain density of peroxynitrite, an indicator of oxidative stress, in the vascular walls is compared between pre-treatment and post treatment patient tissue. Also another comparison is made between pre-treatment and control tissue. The stain density is a software-generated measurement of pixel intensity and is considered to be an arbitrary unit. Higher numbers indicate greater density |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Control No diagnosis of Obstructive Sleep Apnea or treatment with continuous positive airwary therapy | 9 |
| Obstructive Sleep Apnea Participants wear continuous positive airway therapy | 16 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | failure in cpap compliance | 0 | 4 |
Baseline characteristics
| Characteristic | Obstructive Sleep Apnea | Control | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 16 Participants | 9 Participants | 25 Participants |
| Age Continuous | 43.6 years STANDARD_DEVIATION 11.2 | 32.2 years STANDARD_DEVIATION 7.4 | 39.5 years STANDARD_DEVIATION 11.3 |
| Region of Enrollment United States | 16 participants | 9 participants | 25 participants |
| Sex: Female, Male Female | 4 Participants | 5 Participants | 9 Participants |
| Sex: Female, Male Male | 12 Participants | 4 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 9 | 0 / 16 |
| serious Total, serious adverse events | 0 / 9 | 0 / 16 |
Outcome results
Flow Mediated Dilation
A non-invasive test using an ultrasound to measure baseline resting vessel diameter and vessel wall dilation in upper arm post application of an inflated blood pressure cuff for five minutes. The percentage change in vessel wall dilation due to stimulation from the resting vessel diameter will be calculated for each group of participants. The results will be compared relative to each group of participants.
Time frame: Baseline and 12 weeks
Population: Comparative values analyzed for those with endothelial nitric oxide synthase and nitrotyrosine stain density values only.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obstructive Sleep Apnea-pre Treatment | Flow Mediated Dilation | 5.7 percentage change of vessel diamter | Standard Error 0.5 |
| Control | Flow Mediated Dilation | 9.5 percentage change of vessel diamter | Standard Error 0.6 |
| Obstructive Sleep Apnea Post Treatment | Flow Mediated Dilation | 7.3 percentage change of vessel diamter | Standard Error 0.9 |
Peroxynitrite Deposition in the Vascular Walls
A forearm biopsy will be collected to isolate human microcirculatory endothelial cells. The stain density of peroxynitrite, an indicator of oxidative stress, in the vascular walls is compared between pre-treatment and post treatment patient tissue. Also another comparison is made between pre-treatment and control tissue. The stain density is a software-generated measurement of pixel intensity and is considered to be an arbitrary unit. Higher numbers indicate greater density
Time frame: baseline and 12 weeks
Population: Comparative values analyzed for those with endothelial nitric oxide synthase and flow mediated dilation only.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obstructive Sleep Apnea-pre Treatment | Peroxynitrite Deposition in the Vascular Walls | 44.0 stain density units | Standard Error 1.6 |
| Control | Peroxynitrite Deposition in the Vascular Walls | 21.8 stain density units | Standard Error 1.9 |
| Obstructive Sleep Apnea Post Treatment | Peroxynitrite Deposition in the Vascular Walls | 30.5 stain density units | Standard Error 1.6 |